DHA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：本研究的主要目的是确定慢性二十二碳六烯酸（DHA）补充剂是否减缓轻度至中度阿尔茨海默病（AD）患者18个月内认知和功能下降的进展，如ADAS-Cog和CDR-EEG评分的变化所示。 目的：（1）确定长期补充DHA是否减缓了轻度至中度AD患者在18个月内认知和功能下降的进展，如ADAS-cog和CDR-ESTA评分的变化所示;（2）使用这些机制的经验证的生物标志物确定长期补充DHA是否发挥抗淀粉样蛋白、抗氧化剂或神经保护剂的作用;（3）研究长期补充DHA对AD患者血浆和尿液中氧化损伤标志物的影响。 还将确定生物标志物与临床过程之间的关系，以确定这些可获得的生物标志物在临床试验中是否具有有用的作用;（4）确定其他相关微量营养素对AD临床过程的影响，以及对临床过程对DHA补充的反应的影响

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: The primary objective of this study is to determine whether chronic docosahexaenoic acid (DHA) supplementation slows the progression of cognitive and functional decline over 18 months in mild to moderate Alzheimer s disease (AD), as indicated by change in scores on the ADAS-Cog and CDR-SOB. Aims: (1) To determine whether chronic DHA supplementation slows the progression of cognitive and functional decline over 18 months in mild to moderate AD, as indicated by change in scores on ADAS-cog and CDR-SOB; (2) To determine if chronic DHA supplementation exerts anti-amyloid, antioxidant, or neuroprotectant effects, using validated biomarkers of these mechanisms; (3) To determine the effects of chronic DHA supplementation on plasma and urine biomarkers of oxidative damage in AD. The relationship between the biomarker and clinical course will also be determined in order to establish whether these accessible biomarkers have a useful role in clinical trials; (4) To determine the effects of other relevant micronutrients on the clinical course of AD, and on the response of the clinical course to DHA supplementation